Liangkun You

1.2k total citations · 1 hit paper
24 papers, 939 citations indexed

About

Liangkun You is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Liangkun You has authored 24 papers receiving a total of 939 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Liangkun You's work include Autophagy in Disease and Therapy (6 papers), Lung Cancer Treatments and Mutations (6 papers) and MicroRNA in disease regulation (4 papers). Liangkun You is often cited by papers focused on Autophagy in Disease and Therapy (6 papers), Lung Cancer Treatments and Mutations (6 papers) and MicroRNA in disease regulation (4 papers). Liangkun You collaborates with scholars based in China and United States. Liangkun You's co-authors include Weidong Han, Hongming Pan, Jiawei Shou, Ju-Jun Xie, Jing Zhao, Hongsen Li, Xinbing Sui, Zhanggui Wang, Junlin Yao and Jing Jing and has published in prestigious journals such as SHILAP Revista de lepidopterología, Scientific Reports and Cancer Letters.

In The Last Decade

Liangkun You

23 papers receiving 932 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The role of STAT3 in autophagy

2015 418 citations Liangkun You, Zhanggui Wang et al. Autophagy profile →

Peers

Countries citing papers authored by Liangkun You

Since Specialization

Citations

This map shows the geographic impact of Liangkun You's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liangkun You with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liangkun You more than expected).

Fields of papers citing papers by Liangkun You

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liangkun You. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liangkun You. The network helps show where Liangkun You may publish in the future.

Co-authorship network of co-authors of Liangkun You

This figure shows the co-authorship network connecting the top 25 collaborators of Liangkun You. A scholar is included among the top collaborators of Liangkun You based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liangkun You. Liangkun You is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Non small cell lung cancer with SMARCA4 deficiency harboring rare EGFR mutations exhibited significant tumor response when treated with afatinib: a case report 2025 ·Frontiers of Medicine ·Xiaotong Qiu, Liangkun You, (unknown), Sheng Jin	0
2	Exploration and machine learning model development for T2 NSCLC with bronchus infiltration and obstructive pneumonia/atelectasis 2024 ·Scientific Reports ·(unknown), Pan Yang, (unknown), (unknown), Liangkun You, Hongming Pan	1
3	Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review 2024 ·BMC Geriatrics ·(unknown), (unknown), Liangkun You, Na Yan, Jie Dong, (unknown), Yuhong Zhong, (unknown), Hongming Pan	6
4	Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents 2024 ·Frontiers in Pharmacology ·(unknown), Pan Yang, Cheng Cheng, (unknown), (unknown), (unknown), Xinyu Zhu, Hongming Pan, Liangkun You	2
5	Autophagy in colitis-associated colon cancer: exploring its potential role in reducing initiation and preventing IBD-Related CAC development 2023 ·Autophagy ·(unknown), Liangkun You, (unknown), Weidong Han, Hongming Pan	28
6	The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study 2022 ·Scientific Reports ·Liangkun You, (unknown), (unknown), Hongming Pan, Weidong Han	4
7	The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer 2021 ·Frontiers in Oncology ·(unknown), Xiaoling Zhang, Lulu Ren, Liangkun You, (unknown), Hongming Pan, Weidong Han	22
8	Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: A two-center retrospective study 2020 ·International Immunopharmacology ·Junlin Yao, (unknown), Sheng Jin, (unknown), Liangkun You, Xudong Zhu, Hongming Pan, Weidong Han	19
9	Author Correction: Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib 2020 ·Scientific Reports ·Hongming Pan, Zhanggui Wang, Liming Jiang, Xinbing Sui, Liangkun You, Jiawei Shou, Jing Zhao, Ju-Jun Xie, Weiting Ge, Xiujun Cai, Wendong Huang, Weidong Han	2
10	Exploring the role of Mir204/211 in HNSCC by the combination of bioinformatic analysis of ceRNA and transcription factor regulation 2019 ·Oral Oncology ·Jingyi Cai, (unknown), Yuzi Xu, Hao Liu, Jiawei Shou, Liangkun You, Hanliang Jiang, (unknown), Binbin Xie, Weidong Han	5
11	CircUBAP2-mediated competing endogenous RNA network modulates tumorigenesis in pancreatic adenocarcinoma 2019 ·Aging ·Rongjie Zhao, Junjie Ni, Lu Si, (unknown), Liangkun You, Hao Liu, Jiawei Shou, (unknown), Wei Zhang, (unknown), Xinmei Yang, Hongming Pan, Weidong Han	64
12	Analysis of potential genes and pathways associated with the colorectal normal mucosa–adenoma–carcinoma sequence 2018 ·Cancer Medicine ·(unknown), Zhen Liu, Weiting Ge, Jiawei Shou, Liangkun You, Hongming Pan, Weidong Han	26
13	The roles of subcellularly located EGFR in autophagy 2017 ·Cellular Signalling ·Hongsen Li, Liangkun You, Ju-Jun Xie, Hongming Pan, Weidong Han	37
14	Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3 2016 ·Cancer Letters ·Jiawei Shou, Liangkun You, Junlin Yao, Ju-Jun Xie, Jing Jing, Jing Zhao, Liming Jiang, Xinbing Sui, Hongming Pan, Weidong Han	50
15	The role of STAT3 in autophagy breakdown → 2015 ·Autophagy ·Liangkun You, Zhanggui Wang, Hongsen Li, Jiawei Shou, Jing Zhao, Ju-Jun Xie, Xinbing Sui, Hongming Pan, Weidong Han	418
16	Effects of insulin-like growth factor 1 receptor and its inhibitor AG1024 on the progress of lung cancer 2015 ·Journal of Huazhong University of Science and Technology [Medical Sciences] ·Yanhong Wei, Hexiao Tang, Yongde Liao, Shengling Fu, (unknown), (unknown), Chao Zhang, (unknown), (unknown), Liangkun You, Yu Li, Sheng Zhou	11
17	Nuclear factor of activated T cells in cancer development and treatment 2015 ·Cancer Letters ·Jiawei Shou, Jing Jing, Ju-Jun Xie, Liangkun You, Jing Zhao, Junlin Yao, Weidong Han, Hongming Pan	85
18	Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib 2014 ·Scientific Reports ·Hongming Pan, Zhanggui Wang, Liming Jiang, Xinbing Sui, Liangkun You, Jiawei Shou, Jing Zhao, Ju-Jun Xie, Weiting Ge, Xiujun Cai, Wendong Huang, Weidong Han	58
19	Advances in Targeting Insulin-like Growth Factor Signaling Pathway in Cancer Treatment 2014 ·Current Pharmaceutical Design ·Liangkun You, Changyu Liu, Hexiao Tang, Yongde Liao, Shengling Fu	11
20	Crosstalk between IGF-1R and other Tumor Promoting Pathways 2014 ·Current Pharmaceutical Design ·Changyu Liu, Zheng Zhang, Hexiao Tang, (unknown), Liangkun You, Yongde Liao	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact